Clinical trials: BCC - Basal Cell Carcinoma

Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC)

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

• Approved For Marketing
• Age: All ages
• Expanded access

Provide expanded access of cemiplimab in patients with solid tumors

Conditions

Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC)

Trial name

NCT06132191

Testing

Cemiplimab

Sponsor

Regeneron Pharmaceuticals